We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Obsidian Therapeutics, Inc. today announced the presentation of preclinical data on its regulated cytokine programs at the Annual Meeting of the American Association for Cancer Research in Chicago, IL.